Active ingredient description

Anifrolumab is a human immunoglobulin G1 kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1) with high specificity and affinity. This binding inhibits type I IFN signalling thereby blocking the biologic activity of type I IFNs. Inhibition of type I IFN blocks plasma cell differentiation and normalises peripheral T-cell subsets, restoring the balance between adaptive and innate immunity that is dysregulated in SLE.

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code Group title Classification
L04AG11 L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG11

Product monographs

Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):

Title Information Source Document Type  
SAPHNELO Concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC

External identifiers

CAS Substance: 1326232-46-5
DrugBank Drug: DB11976
RxNorm Ingredient: 2565276
UNII Identifier: 38RL9AE51Q


Anifrolumab is an active ingredient of these brands:

United States (US)

Australia (AU)

Austria (AT)

Canada (CA)

Croatia (HR)

Estonia (EE)

France (FR)

Ireland (IE)

Israel (IL)

Italy (IT)

Japan (JP)

Lithuania (LT)

Poland (PL)

Romania (RO)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.